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Abstract: The risk of adverse effects of nitrous oxide (N2O) exposure is insufficiently recognized despite
its widespread use. These effects are mainly reported through case reports. We conducted an individual
patient data meta-analysis to assess the prevalence of clinical, laboratory, and magnetic resonance
findings in association with N2O exposure in medical and recreational settings. We calculated the
pooled estimates for the studied outcomes and assessed the potential bias related to population
stratification using principal component analysis. Eighty-five publications met the inclusion criteria
and reported on 100 patients with a median age of 27 years and 57% of recreational users. The most
frequent outcomes were subacute combined degeneration (28%), myelopathy (26%), and generalized
demyelinating polyneuropathy (23%). A T2 signal hyperintensity in the spinal cord was reported
in 68% (57.2–78.8%) of patients. The most frequent clinical manifestations included paresthesia
(80%; 72.0–88.0%), unsteady gait (58%; 48.2–67.8%), and weakness (43%; 33.1–52.9%). At least
one hematological abnormality was retrieved in 71.7% (59.9–83.4%) of patients. Most patients had
vitamin B12 deficiency: vitamin B12 <150 pmol/L (70.7%; 60.7–80.8%), homocysteine >15 µmol/L
(90.3%; 79.3–100%), and methylmalonic acid >0.4 µmol/L (93.8%; 80.4–100%). Consistently, 85% of
patients exhibited a possibly or probably deficient vitamin B12 status according to the cB12 scoring
system. N2O can produce severe outcomes, with neurological or hematological disorders in almost all
published cases. More than half of them are reported in the setting of recreational use. The N2O-related
burden is dominated by vitamin B12 deficiency. This highlights the need to evaluate whether correcting
B12 deficiency would prevent N2O-related toxicity, particularly in countries with a high prevalence
of B12 deficiency.
Keywords: global health; global burden related to nitrous oxide exposure; medical and recreational
settings; individual patient data meta-analysis; nitrous oxide-related toxicity; vitamin B12 deficiency;
one-carbon metabolism; homocysteine; methylmalonic acid
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1. Introduction
Nitrous oxide (N2O) is a colorless, sweet-smelling gas that has been widely used in dental,
emergency, and anesthetic practices. The first use of N2O as an anesthetic agent was reported on
December 1844 by Dr. Horace Wells, an American dentist who demonstrated insensitivity to pain from
a dental extraction after N2O inhalation [1]. Before proposing the use of N2O as an anesthetic agent,
Dr. Wells had attended a demonstration by Gardner Quincy Colton regarding the use of N2O as an
exhilarating or laughing gas [2]. Joseph Priestley, a British scientist, reported the discovery of N2O in
1772, and since that time the inhalation of this gas as part of the public entertainment had become
commonplace [3]. Owing to its physical and chemical properties N2O is also used in the food industry
as a mixing, foaming, and propellant for the preparation of whipping cream.
It is well known that exposure to N2O is associated with a risk of developing neurological
and hematological complications [4]. In 1956, Lassen et al. reported the first description of severe
bone-marrow depression after prolonged N2O anesthesia for treating patients with tetanus [4,5].
In one patient from this series, the bone-marrow biopsy on the fifth day of N2O anesthesia revealed
“strikingly megaloblastic” erythropoiesis and changes in granulocytopoiesis that were typical of
“pernicious anemia” [5]. Since this first description of a potential link between N2O exposure and
myelosuppression, the hypothesis of a disorder related to vitamin B12 metabolism was suggested [6].
The effects of N2O exposure are mainly reported through case reports. However, the global burden
related to N2O exposure, notably regarding its effects on one-carbon metabolism, has never been
subject to meta-analysis. Thus, we conducted individual patient data meta-analysis to assess the
prevalence of clinical, laboratory, and magnetic resonance findings in association with N2O exposure
in medical and recreational settings.
2. Matherials and Methods
2.1. Data Sources and Searches
The literature search was conducted using MEDLINE®-indexed literature using the PubMed search
engine from the National Centre for Biotechnology Information (www.pubmed.gov) (January 1966
to August 2018) using the following full electronic search strategy: ((protoxide[All Fields] AND
(“nitrogen”[MeSH Terms] OR “nitrogen”[All Fields])) OR “Nitrous oxide”[All Fields] OR “nitrogen
protoxide”[All Fields] OR “laughing gas”[All Fields] OR whippet[All Fields] OR whippets[All
Fields]) AND (b12[All Fields] OR “vitamin b12”[All Fields] OR (“vitamin B12”[MeSH Terms]
OR “vitamin B12”[All Fields] OR “cobalamin”[All Fields]) OR (“homocysteine”[MeSH Terms] OR
“homocysteine”[All Fields]) OR “methylmalonic acid”[All Fields] OR (“methionine”[MeSH Terms] OR
“methionine”[All Fields]) OR “folic Acid”[All Fields]). Additional articles were retrieved from primary
search references. EndNote X7.8 was used for reference management [7]. The present systematic
review was performed in accordance with the MOOSE (Meta-analysis Of Observational Studies in
Epidemiology) Statement [8].
2.2. Study Selection
We retained a case report in the systematic review if it reported the description of at least
one health outcome in relation to previous N2O exposure. The exclusion criteria were as follows:
non-English language publication; editorial; narrative review; congress abstract; absence of N2O
exposure; preventive treatment with vitamin B12 before N2O exposure; and no reported data on at
least one of the following biological parameters before vitamin B12 therapy: hemoglobin, hematocrit,
mean corpuscular volume (MCV), serum folate, homocysteine, or methylmalonic acid.
2.3. Data Extraction
Three investigators (A.O.; J.L.; J.-L.G.) reviewed the titles and abstracts of all citations identified by
the literature search. Eligible articles were reviewed by eight investigators (A.O.; M.J.; J.L.; O.H.; C.F.;
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C.S.; E.L.; M.W.; P.F.T.). Disagreement in data extraction was resolved by consensus. The following data
were extracted using a predefined extraction form structured in 10 domains: Domain #1: Case report
characteristics (Author, Year, Country); Domain #2: Patient’s demographics (Age, Gender); Domain #3:
Clinical manifestations expressed as binary outcomes (Group 1: Paresthesia of extremities, numbness,
or tingling; Quadriparesis or paralysis; Unsteady gait or walking difficulty; Falling, Equilibrium
troubles; Weakness; Paraplegia; Hypotonia; Lhermitte sign; Athetoid movement; Ataxia; Seizures;
Spasm; Urinary incontinence; Urine retention; Fecal incontinence; Vertigo; Syncope; Polyneuropathy;
Bulbar paralysis; Cognitive decline; Impaired memory; Confusion; Disorientation; Lethargy;
Neurological deterioration; Group 2: Behavior alteration; Paranoid behavior; Visual hallucination;
Agitation; Depression; Suicidal thought; Group 3: Neck pain; Foot pain; Chest pain; Headache;
Painful erection; Abdominal pain; Group 4: Constipation, Anorexia, Vomiting; Group 5: Tachypnea;
Apnea; Respiratory paralysis; Group 6: Decreased libido; Hyperpigmentation; Domain #4: Laboratory
findings expressed as continuous outcomes [hemoglobin (g/L); hematocrit (%); MCV (fL); vitamin
B12 (pmol/L); folate (µg/L); homocysteine (µmol/L); methylmalonic acid (µmol/L)]; We calculated the
combined indicator of vitamin B12 status score (cB12) by combining vitamin B12, homocysteine and
methylmalonic acid according the Fedosov et al. [9]. The cB12 score defines five vitamin B12 states, as
follows: 2 = elevated B12 (cB12 ≥ 1.5), 1 = adequate B12 status (cB12: −0.5 to 1.5), −1 = decreased B12
(cB12: −1.5 to−0.5; start B12 supplements),−2 = possibly B12 deficient (cB12: −2.5 to−1.5; start oral B12),
−3 = probably B12 deficient (cB12 < 2.5; start B12 injections); Domain #5: Reported diagnoses expressed
as binary outcomes (Subacute combined degeneration; Generalized demyelinating polyneuropathy;
Myelopathy; Axonal polyneuropathy; Encephalopathy; Recurrent paraparesis; N2O-related toxicity;
Vitamin B12 deficiency; MTHFR deficiency; No specific diagnosis applied); Domain #7: Setting of
N2O exposure expressed as binary outcomes (Recreational use; Surgery; Occupational exposure;
Pain management; Manipulation under GA; Sleep disturbance; and Munchausen); Domain #9: N2O
exposure quantification (frequency: short or regular exposure as defined below; duration of N2O
exposure in years; N2O presentation: cartridge, canister, whippets cream bulbs, anesthesia machine
for medical use, or anesthesia machine for personal use); Domain #10: Magnetic resonance findings
expressed as binary outcomes (presence or absence of a T2 signal hyperintensity in the spinal cord).
2.4. Nitrous Oxide Exposure
Regular N2O exposure was defined as repeated exposure to N2O, especially in a recreational
setting, pain management or occupational exposure, with minimum consumption of one cartridge per
month. For each patient, we estimated the average number of cartridges consumed per day and the
duration of exposure in years. In the recreational setting, N2O was commonly available in the form
of small pressurized cartridges which can deliver the equivalent of 8 liters of N2O gas at standard
temperature and pressure (8 g) [3]. We quantified the exposure to N2O using the following formula:
Amount of N2O exposure = (average number of cartridges consumed per day × duration of exposure
expressed in years).
2.5. Main Outcomes and Measures
The primary outcome of the systematic review was to report on the clinical, laboratory,
and magnetic resonance findings of subjects who were exposed to N2O in medical and recreational
settings. Main clinical findings: Paresthesia in extremities, numbness, tingling; Unsteady gait,
walking difficulty; Weakness; Fallings or equilibrium disorders; Lhermitte’s sign; and Ataxia.
Laboratory findings: Hemoglobin; Hematocrit; MCV; Vitamin B12; Folate; Homocysteine;
and Methylmalonic acid. Magnetic resonance finding: Presence of T2 signal hyperintensity in
the spinal cord. We assessed two secondary outcomes: (1) to look for predictors of regular N2O
exposure; (2) to assess the potential association between N2O exposure and health outcomes.
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2.6. Data Synthesis and Analysis
Categorical variables were summarized as frequency counts and percentages with the 95%
confidence interval (95% CI). Quantitative variables were expressed as medians and interquartile
range (IQR, 25th and 75th percentiles). We compared proportions using the chi-square test or Fisher’s
exact test as appropriate. Medians were compared using the Mann–Whitney U test. We assessed
correlations using Spearman’s rank correlation coefficient. To derive predictors of short N2O exposure,
we performed univariate logistic regression analysis on binary and continuous variables, using the
“Short N2O exposure” item as a dependent variable. When a continuous variable was significantly
associated with a short N2O exposure, we carried out receiver operating characteristic (ROC) analysis
for defining its optimal cut-off using the “Short exposure to N2O” item as a classification variable [10].
The optimal cut-off was defined using the Youden index J [11]. Receiver operating characteristic
analysis outputs included the area under the ROC curve (AUROC), the 95% CI, and the associated
p-value using the exact binomial method. In multivariate analysis, all significant items resulting
from the univariate logistic regression were integrated into a multivariate logistic regression model
using the stepwise method. All variables with p < 0.1 were included in the model and variables
with P < 0.05 were retained in the model. Results were shown as odds ratios (ORs) and 95% CI.
We assessed model discrimination using ROC analysis and model calibration using the Hosmer and
Lemeshow goodness-of-fit test. All statistical analyses were conducted using the SAS® 9.4 platform
(Cary, NC, USA) and MedCalc for Windows v16.8.4 (Ostend, Belgium) based on a two-sided type I
error with an alpha level of 0.05.
2.7. Assessment of Bias
We assessed the potential bias related to population stratification using principal component
analysis. We used all the variables related to clinical findings, laboratory findings, reported diagnoses,
and N2O exposure settings to calculate the ten top eigenvalues. For each patient, the principal
components were calculated according to each eigenvalue. We assessed population stratification by
visual inspection using two-dimensional and three-dimensional diagrams. The principal component
analysis was conducted using SVS 8.8.1 (Golden Helix, Inc. Bozeman, MT, USA).
3. Results
3.1. Literature Review
The systematic search generated 513 citations of which 132 appeared to be relevant to the systematic
review. Of these 132 studies, 47 were not retained by the selection criteria (Table S1), leaving 85 eligible
publications (Figure 1 and Table S2). All the case reports included in the systematic review reported
individual-level data on 100 patients. Among the 100 reports, most originated from North America
(n = 51), Western Europe (n = 22), China/Taiwan (n = 12) and Australia/New Zealand (n = 10).
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Munchausen syndrome 100 1 1.0 (0–3.0) 
Management of sleep disturbance 100 1 1.0 (0–3.0) 
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Once 100 24 24.0 (15.5–32.5) 
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3.2. Prevalence of Clinical, Laboratory and Magnetic Resonance Findings in Association with N2O Exposure
Among the 100 patients included in the systematic review, the male:female gender distribution
was 60:40 and the median age was 27 years (IQR, 22–36; range, 0.4–76.0). Most patients included in the
meta-analysis were exposed to N2O in the setting of recreational use (57%) or surgery (25%) (Table 1).
Seventy-six percent (76/100) of patients had regular exposure to N2O. Among them, recreational use
(73.7%, 56/76), occupational exposure (11.8%, 9/76), and pain management (7.9%, 6/76) represented
the three main N2O exposure modes. Among regular users, the median N2O exposure was
18.5 cartridge-years, corresponding to a total amount of 54,020 g of N2O. The three most frequently
reported diagnoses were subacute combined degeneration (28%), myelopathy (26%), and generalized
demyelinating polyneuropathy (23%). A T2 signal hyperintensity in the spinal cord was reported in
68% of patients who underwent magnetic resonance imaging of the spinal cord (Table 2).
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Table 1. Settings and Quantification of Nitrous Oxide Exposure Among Patients Included in the
Individual Patient Data Meta-Analysis.
Setting of nitrous oxide exposure N n Percentage (95% CI)
Recreational 100 57 57.0 (47.1–66.9)
Surgery 100 25 25.0 (16.4–33.6)
Occupational exposure 100 9 9.0 (3.3–14.7)
Pain management 100 6 6.0 (1.3–10.7)
Manipulation under general anesthesia 100 1 1.0 (0–3.0)
Munchausen syndrome 100 1 1.0 (0–3.0)
Management of sleep disturbance 100 1 1.0 (0–3.0)
Frequency of nitrous oxide exposure N n Percentage (95% CI)
Regular 100 76 76.0 (67.5–84.5)
Once 100 24 24.0 (15.5–32.5)
Quantitative estimates of nitrous oxide exposure* n Median IQR (25th–75th)
Number of nitrous oxide cartridge per day 30 25 8–85
Duration of nitrous oxide duration (year) 52 0.7 0.3–1.5
Quantification of nitrous oxide exposure (cartridge-years) 28 18.5 1.4–99.9
IQR: interquartile range; N: number of studied patients; n: number of observations. * Among patients with regular
nitrous oxide exposure.
Table 2. Magnetic Resonance Findings and Diagnoses Among the Patients Included in the Individual
Patient Data Meta-Analysis.
Magnetic resonance imaging findings N n Percentage (95% CI)
Presence of T2 signal hyperintensity in the spinal cord 75 51 68.0 (57.2–78.8)
Reported diagnoses* N n Percentage (95% CI)
Subacute combined degeneration 100 28 28.0 (19.0–37.0)
Myelopathy 100 26 26.0 (17.3–34.7)
Generalized demyelinating polyneuropathy 100 23 23.0 (14.6–31.4)
Vitamin B12 deficiency 100 14 14.0 (7.1–20.9)
Axonal polyneuropathy 100 11 11.0 (4.8–17.2)
Encephalopathy 100 2 2.0 (0–4.8)
Recurrent paraparesis 100 1 1.0 (0–3)
MTHFR deficiency 100 1 1.0 (0–3)
Toxicity due to N2O with no specific diagnosis applied 100 19 19.0 (11.2–26.8)
N: total number of studied patients; n: number of observations; N2O: nitrous oxide. * Any patient could have more
than one diagnosis applied.
At least one neurological symptom was reported in 96% (92.1–99.9%) of patients and included
the following clinical manifestations by decreasing order of frequency: paresthesia in the extremities
(80%), unsteady gait or walking difficulties (58%), weakness (43%), fallings or equilibrium disorders
(24%), Lhermitte’s sign (15%), and ataxia (12%) (Table 3 and Figure 2).
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Table 3. Clinical Findings Among the Patients Included in the Individual Patient Data Meta-Analysis.
Clinical Findings N n Percentage (95% CI)
Paresthesia in extremities, numbness, tingling 100 80 80.0 (72.0–88.0)
Unsteady gait, walking difficulty 100 58 58.0 (48.2–67.8)
Weakness 100 43 43.0 (33.1–52.9)
Fallings or equilibrium disorders 100 24 24.0 (15.5–32.5)
Lhermitte’s sign 100 15 15.0 (7.9–22.1)
Ataxia 100 12 12.0 (5.5–18.5)
Cognitive decline 100 9 9.0 (3.3–14.7)
Urinary incontinence 100 8 8.0 (2.6–13.4)
Quadriparesis or paralysis 100 7 7.0 (1.9–12.1)
Behavior alteration 100 6 6.0 (1.3–10.7)
Urine retention 100 5 5.0 (0.7–9.4)
Impaired memory 100 5 5.0 (0.7–9.4)
Headache 100 4 4.0 (0.1–7.9)
Depression 100 4 4.0 (0.1–7.9)
Thrombo-occlusive event 100 3 3.0 (0–6.4)
Mental confusion 100 3 3.0 (0–6.4)
Constipation 100 3 3.0 (0–6.4)
Paranoid behavior 100 3 3.0 (0–6.4)
Foot pain 100 3 3.0 (0–6.4)
Hyperpigmentation 100 3 3.0 (0–6.4)
Abdominal pain 100 3 3.0 (0–6.4)
Agitation 100 2 2.0 (0–4.8)
Fecal incontinence 100 2 2.0 (0–4.8)
Lethargy 100 2 2.0 (0–4.8)
Seizures 100 2 2.0 (0–4.8)
Decreased libido 100 2 2.0 (0–4.8)
Visual hallucination 100 2 2.0 (0–4.8)
Anorexia 100 1 1.0 (0–3)
Apnea 100 1 1.0 (0–3)
Athetoid movement 100 1 1.0 (0–3)
Bulbar paralysis 100 1 1.0 (0–3)
Chest pain 100 1 1.0 (0–3)
Disorientation 100 1 1.0 (0–3)
Hypotonia 100 1 1.0 (0–3)
Neck pain 100 1 1.0 (0–3)
Painful erection 100 1 1.0 (0–3)
Paraplegia 100 1 1.0 (0–3)
Polyneuropathy 100 1 1.0 (0–3)
Respiratory paralysis 100 1 1.0 (0–3)
Spasm 100 1 1.0 (0–3)
Suicidal thought 100 1 1.0 (0–3)
Syncope 100 1 1.0 (0–3)
Tachypnea 100 1 1.0 (0–3)
Vertigo 100 1 1.0 (0–3)
Vomiting 100 1 1.0 (0–3)
N: total number of studied patients; n: number of observations.
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Figure 2. Proportion (95% confidence interval) of main clinical, laboratory and radiological findings
in patients exposed to nitrous oxide (N2O). Low hemoglobin status was defined according to WHO
guidelines (<13.0 g/dL in men; <12.0 g/dL in nonpregnant women) [12]. Low hematocrit status was
defined according to WHO guidelines (<39 in en; <36% in nonpregnant women) [12].
Patients had a high risk of macrocytic anemia with a median MCV of 100 fL (IQR: 94–103)
and median values of hemoglobin of 12.8 g/dL (IQR: 10.8–14.2) and 10.7 g/dL (IQR: 8.3–12.4) in
males and females, respectively. At least one hematological abnormality was retrieved in 71.7%
of cases (59.9–83.4%). The proportions of patients with low hemoglobin level (<13.0 g/dL in men;
<12.0 g/dL in women, based on WHO guidelines [12]), low hematocrit level (<39% in men; <36% in
nonpregnant women, based on WHO guidelines [12]), and MCV >100 fL were 55.8%, 52.4%, and 41.8%,
respectively (Table 4 and Figure 2).
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Table 4. Laboratory Findings Among the Patients Included in the Individual Patient Data Meta-Analysis.
Laboratory findings (continuous) n Median IQR (25th–75th)
Hemoglobin (g/dL)* 43 12.0 9.1–13.3
Males 23 12.8 10.8–14.2
Females 20 10.7 8.3–12.4
Hematocrit (%)† 21 38 33–42
Males 13 40 33–44
Females 8 35 32–39
Mean corpuscular volume (fL) 55 100 94–103
Vitamin B12 (pmol/L) 82 101 74–161
Folate (serum) (µg/L) 20 12.8 7.3–14.6
Homocysteine (µmol/L) 31 55 29–111
Methylmalonic acid (µmol/L) 16 5.0 1.1–6.6
Combined indicator of vitamin B12 status 33 −2.802 −3.368–−1.924
Laboratory findings (dichotomized) N n Percentage (95%, CI)
Low hemoglobin status* 43 24 55.8 (40.3–71.3)
Low hematocrit status† 21 21 52.4 (29.1–75.7)
Mean corpuscular volume >100 fL 55 23 41.8 (28.4–55.3)
Vitamin B12 < 150 pmol/L 82 58 70.7 (60.7–80.8)
Folate (serum) <7 µg/L 20 5 25.0 (4.2–45.8)
Homocysteine >15 µmol/L 31 28 90.3 (79.3–100)
Methylmalonic acid >0.4 µmol/L 16 15 93.8 (80.4–100)
Combined indicator of vitamin B12 status‡
2 = elevated B12 (cB12 ≥ 1.5) 33 0 0.0 (—)
1 = adequate B12 status (cB12: −0.5 to 1.5) 33 3 9.1 (0–19.4)
−1 = decreased B12 (cB12: −1.5 to -0.5) 33 2 6.1 (0–14.7)
−2 = possibly B12 deficient (cB12: −2.5 to −1.5) 33 9 27.3 (11.2–43.3)
−3 = probably B12 deficient (cB12 < −2.5) 33 19 57.6 (39.8–75.4)
IQR: interquartile range; N: total number of studied patients; n: number of observations. *Low hemoglobin status
was defined according to WHO guidelines (<13.0 g/dL in men; <12.0 g/dL in nonpregnant women) [12]. † Low
hematocrit status was defined according to WHO guidelines (<39% in men; <36% in nonpregnant women) [12].
‡ The combined indicator of vitamin B12 status (cB12) score was calculated according to Fedosov et al. [9].
Regarding one-carbon metabolism markers, the median plasma vitamin B12 concentration was
low (101 pmol/L, IQR: 74–161) with 70.7% of patients exhibiting a vitamin B12 level <150 pmol/L,
considered as the threshold of vitamin B12 deficiency. The median plasma concentrations of
homocysteine and methylmalonic acid were 55 µmol/L (IQR, 29–111) and 5.0 µmol/L (IQR: 1.1–6.6),
respectively, with a vast majority of patients exhibiting high homocysteine (>15 µmol/L) and
methylmalonic acid (>0.4 µmol/L) levels (90.3% and 93.8%, respectively). According to the cB12 scoring
system, 90.9% of patients exhibited at least a decreased vitamin B12 status and 84.8% of patients
exhibited a possibly or probably deficient vitamin B12 status (Figure 3). The serum folate concentration
was in the normal reference range with a median of 12.8 µg/L (IQR, 7.3–14.6) (Table 4).
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Figure 3. Vitamin B12 status according to the combined indicator of vitamin B12 status (cB12) scoring
system. The cB12 score was calculated according to Fedosov et al. [9]. Proportion (95% confidence
interval) of main clinical, laboratory and radiological findings in patients exposed to nitrous oxide (N2O).
Low hemoglobin status was defined according to WHO guidelines (<13.0 g/dL in men; <12.0 g/dL in
nonpregnant women) [12]. Low hematocrit status was defined according to WHO guidelines (<39% in
men; <36% in nonpregnant women) [12].
3.3. Secondary Outcomes
3.3.1. Predictors of Short Nitrous Oxide Exposure
Univariate Analysis
In univariate logistic regression analysis, among all the variables screened in the systematic
review (63 variables: demographics, n = 2; clinical findings, n = 44; laboratory findings, n = 7;
magnetic resonance finding, n = 1; reported diagnoses, n = 9) only three were significantly associated
with a short N2O exposure, namely: age, vitamin B12 concentration, and MCV (Table 5 and Table
S3). In ROC analysis, age, vitamin B12 concentration, and MCV had a significant optimal cut-off
in association with a short N2O exposure (Table 5). The dichotomized predictors were significantly
associated with a short N2O exposure in univariate logistic regression: age ≥40 years (OR = 23.33, 95%
CI: 6.84–79.61); vitamin B12 ≤74 pmol/L (OR = 6.06, 95% CI: 2.05–17.90), and MCV >100 fL (OR = 9.75,
95% CI: 1.93–49.15) (Table 5).
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Table 5. Factors Associated with a Short Exposure to Nitrous Oxide in Univariate and Multivariate Analyses.
Predictor Short Exposure toN2O, Median (IQR)
Regular Exposure to
N2O, Median (IQR)
AUROC†
Defined
Cut-Off
AUROC,
p-Value
Univariate LR*,
OR (95% CI)
Univariate LR*,
p-Value
Multivariate LR‡,
OR (95% CI)
Multivariate
LR‡, p-Value
Age
(years)
47
(25–58)
26
(22–33) ≥40 0.0076
23.33
(6.84–79.61) < 0.0001
23.95
(3.62–158.61) 0.001
Vitamin B12
(pmol/L)
74
(33–104)
110
(81–194) ≤74 0.0002
6.06
(2.05–17.90) 0.001
10.57
(1.70–65.90) 0.01
MCV
(fL)
104
(101–110)
97
(92–101) >100 <0.0001
9.75
(1.93–49.15) 0.006 Not retained§ Not retained§
95% CI: 95% confidence interval; AUROC: area under the receiver operating characteristic curve; IQR: interquartile range; LR: logistic regression; MCV: mean corpuscular volume; OR:
odds ratio. * Univariate logistic regression analysis on dichotomized variables; † Classification variable: Short nitrous oxide exposure; ‡Multivariate logistic regression analysis on
dichotomized variables using the stepwise method; § Not retained in the multivariate logistic regression model.
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Multivariate Analysis
Among the variables retained in univariate logistic regression, two remained significant in
multivariate logistic regression and were independently associated with a short N2O exposure, namely:
age ≥40 years (OR = 23.95, 95% CI: 3.62–158.61; p = 0.001) and vitamin B12 ≤74 pmol/L (OR = 10.57,
95% CI: 1.70–65.90; p = 0.01) (Table 5). The multivariate regression model was well-calibrated and
exhibited a good discrimination (AUROC = 0.908; 95% CI: 0.795–0.970) and overall model fit (Cox and
Snell R2 = 0.42; Nagelkerke R2 = 0.60; p <0.0001).
3.3.2. Association Between the Amount of Nitrous Oxide Exposure and Outcomes
Data regarding the amount of N2O exposure was available in 28 patients. In exploratory
analyses, the amount of N2O exposure was not significantly correlated with any biological variable.
Furthermore, the amount of N2O exposure was not significantly associated with the most frequently
reported diagnoses (subacute combined degeneration, generalized demyelinating polyneuropathy,
and myelopathy), the most commonly reported clinical findings (paresthesia in extremities, numbness,
tingling; unsteady gait, walking difficulty; weakness; and fallings or equilibrium disorders), or the
presence of T2 signal hyperintensity in the spinal cord (Table S4).
3.3.3. Assessment of Bias
The visual inspection of 2-D and 3-D plots from the principal component analysis, based on the
top five eigenvalues, did not reveal any significant population stratification that could be suggestive of
a high risk of bias (Figure S1).
4. Discussion
The present meta-analysis highlights the potential side-effects related to N2O use with a particularly
unfavorable risk-benefit ratio for recreational users who represent more than half of the reported
subjects. Among patients with N2O-related toxicity, neurological or hematological disorders were
observed in almost all patients (96%). The N2O-related burden is dominated by vitamin B12 deficiency
and the associated alterations in one-carbon metabolism markers.
Three-quarter of patients with N2O-related toxicity exhibited a low vitamin B12 status
(<150 pmol/L). Consistently, 85% of patients exhibited a possibly or probably deficient vitamin
B12 status according to the cB12 scoring system. In the human body, vitamin B12 is physiologically
active in two forms: 1) methylcobalamin which represents a cofactor for the methyltransferase enzyme
5-methyltetrahydrofolate-homocysteine methyltransferase, also known as methionine synthase (MTR),
and 2) adenosylcobalamin which serves as a cofactor for the enzyme methylmalonyl coenzyme A mutase
(MMCoAM) [13–23]. A defect in MMCoAM activity leads to an accumulation of methylmalonic acid
while a defect in MTR activity leads to a decrease of methionine and an increase of both homocysteine
and S-adenosyl-homocysteine as well as methyltetrahydrofolate concentrations [24]. In the present
meta-analysis, vitamin B12 deficiency was evidenced by hyperhomocysteinemia >15 µmol/L and
methylmalonic acid >0.4 µmol/L in more than 90% of patients with N2O-related toxicity. N2O exposure
is well described as the most effective way to produce vitamin B12 deficiency in animal models [24–27].
N2O induces oxidation of the active cobalt center contained in the vitamin B12 chemical structure.
It also induces a displacement of the vitamin B12 molecule from MTR with a parallel loss of MTR
activity [24].
Several mechanistic hypotheses have been advanced for explaining the association between
N2O exposure and the occurrence of clinical and biochemical abnormalities associated with vitamin
B12 deficiency, notably subacute combined degeneration of the spinal cord in association with
hyperhomocysteinemia and elevated levels of methylmalonic acid. Hathout & El-Saden nicely
described these hypotheses in their review paper regarding N2O-induced myelopathy [24]. Three main
mechanistic hypotheses have been put forward as the knowledge in the field progressed: the alteration
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of the MMCoAM pathway [24], the alteration of the methylcobalamin-MTR pathway [24,28,29],
and more recently, the imbalance between cytokines and growth factors exhibiting myelinotoxic
or myelinotrophic effects [30–34]. Early observations initially suggested that the toxicity of N2O
occurred primarily through the MMCoAM pathway. However, this was challenged by clinical
observations in patients with monogenic inherited disorders associated with methylmalonic acidemia
who do not develop subacute combined degeneration [24]. The second hypothesis underlying the
relationship between N2O exposure and neurological complications is the effect of N2O on the
methylcobalamin-MTR pathway. Indeed, inherited disorders in MTR activity induce a decrease of
methionine and a low methyl-donor status with defective methylation and resulting instability of the
myelin sheath. However, this hypothesis was hampered by experiments using the B12-deficient fruit
bat animal model. These experiments did not show significant alterations in S-adenosyl-methionine and
S-adenosyl-homocysteine in the brain and spinal cord after induction of severe vitamin B12 deficient
myelopathy following a combination of dietary deprivation and N2O exposure [24,28,29]. During the
last two decades, much progress has been made in the field of neuroimmunology and have suggested
that the pathogenesis of N2O-induced myelopathy could be explained by an imbalance between
cytokines and growth factors exhibiting myelinotoxic (tumor necrosis factor alpha, sCD40:sCD40L dyad,
nerve growth factor) or myelinotrophic (interleukin-6 and epidermal growth factor) effects [30–34].
The present meta-analysis reports that patients with regular N2O exposure exhibited high
methylmalonic acid concentrations. In an experimental rat model, the exposure to 50% N2O and 50%
O2 mixture during 48 h was associated with a 70% reduction of MTR activity in the liver, kidney,
and brain with no significant changes in the activity of MMCoAM [35]. Prolonged exposure to 50%
N2O induced a further decrease in both MTR and MMCoAM activities (12% and 32% of control values
after 33 days, respectively). This experiment demonstrates the time-dependent effect that N2O exerts
on the reduction of enzymatic activity of MTR and MMCoAM. The effect of N2O on MTR is evident
from the first hours of exposure, while the effect on the MMCoAM requires longer exposure times [35].
Prolonged exposure to N2O causes a decrease in the activity of both MTR and MMCoAM with harmful
effects on one-carbon metabolism markers [35].
In the present meta-analysis, age ≥40 years, a vitamin B12 concentration ≤74 pmol/L, and an
MCV >100 fL were associated with a short N2O exposure, mostly associated with surgery and
a more severe clinical picture. These data are in keeping with those of the ENIGMA trial that
assessed the effects of N2O on patients’ outcome after major surgery [36]. In this multicenter
randomized trial, 215 patients undergoing N2O-containing general anesthesia were compared with
179 patients undergoing N2O-free general anesthesia [36]. The N2O group exhibited a significantly
increased risk of postoperative hyperhomocysteinemia defined by rising to the 90th percentile of
the preoperative homocysteine concentration (>13.5 µmol/L) (OR = 3.91; 95% CI: 1.82–8.40) [36].
Importantly, the occurrence of postoperative hyperhomocysteinemia was significantly associated with
an increased risk of complications (risk ratio (RR) = 2.8; 95% CI: 1.4–5.4) and cardiovascular events
(RR = 5.1; 95% CI: 3.1–8.5) [36].
The present meta-analysis reports that almost three-quarters of patients regularly exposed to
N2O were recreational users. The use of N2O as a “laughing gas” became popular in the early 1800s
during aristocratic laughing gas parties. Over time, the social image of N2O as a recreational agent
has shifted from a “high-society drug” to a “psychedelic drug”, ending up during the last decade
as a “hippie crack drug.” The 2016/17 Crime Survey for England and Wales reported that 2.6% of
adults aged 16–59 (around 840,000 people) had used N2O in the preceding year [37]. Among the
youngest subjects, the prevalence of N2O use was dramatically higher with 9.3% of 16–24 year olds
reported using N2O (males, 11.1%; females, 7.4%) in the preceding year [37]. The Global Drug
Survey 2014 (GDS2014), conducted in 17 countries out of 74,864 participants, confirmed the increasing
popularity of N2O as a recreational drug with a lifetime prevalence of 38.6% and 29.4% in the UK and
US, respectively [38]. Among N2O users, the reported rates for persistent numbness and accidental
injury were 4.3% and 1.2%, respectively [38]. The updated results from the GDS2016, with over
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100,000 respondents from over 50 countries, confirmed that 4% of N2O users had symptoms of nerve
damage [39]. These data highlight the fact that the recreational use of N2O represents a significant public
health issue. Awareness campaigns among high-risk populations are eagerly needed, particularly for
the 16–24 year olds. Most cases of N2O-related toxicity were reported in world areas and countries
with a low prevalence of B12 deficiency, including North America and Western Europe. Few reports
originated from Turkey and Iran, two Middle Eastern countries with an intermediate-to-high prevalence
of vitamin B12 deficiency. This highlights the lack of published data that would allow analyzing the
risk of N2O-related outcomes in exposed subjects from countries with a high prevalence of vitamin
B12 deficiency, including India, sub-Saharan Africa, and Mexico (Figure S2).
The medical community, particularly physicians who are involved in the emergency departments,
anesthesiologists, and surgeons, should be aware of the magnitude of recreational N2O exposure in the
general population [3]. The evaluation of a patient with a suspicion of N2O-induced toxicity should
include a rigorous clinical evaluation including neurological examination, a laboratory evaluation
which consists of a complete blood count, vitamin B12, homocysteine, methylmalonic acid, and folate,
and MRI studies where indicated. Patients requiring N2O-containing anesthesia, particularly those in
the setting of elective surgery, should have the same systematic biochemical assessment. In the ENIGMA
trial, the vitamin B supplementation before surgery was associated with a significant reduction of
the risk for developing post-operative hyperhomocysteinemia (OR = 0.09; 95% CI: 0.03–0.28) [36].
Thus, a strategy based on preoperative screening and the correction of a possible vitamin B12 deficiency,
notably in high-risk populations (elderly, vegan, and chronically ill patients) could reduce the risk of
N2O-related disorders.
Two systematic reviews assessed N2O-related toxicity in recreational use and general anesthesia
settings. Garakani et al. reported the main findings related to chronic N2O abuse with a focus on
neurological sequelae and psychiatric disorders [4]. In this systematic review, no summary effect was
calculated regarding medical, laboratory, and radiological findings. Furthermore, biological findings
were assessed as categorical variables, and no univariate or multivariate analyses were performed.
The authors concluded that chronic N2O abuse represents a potentially difficult-to-diagnose condition
which could lead to death and that physicians should be aware of N2O-related toxicity. In the setting
of anesthesia, a meta-analysis summarized the evidence from randomized clinical trials associating
N2O with serious cardiovascular complications [40]. This meta-analysis concluded on the lack of
robust evidence for how N2O used as part of general anesthesia affects mortality and cardiovascular
complications [40].
The present meta-analysis has several strengths. First, we report an individual patient
data meta-analysis that collected original data from 100 patients to describe the global burden
related to N2O toxicity. This approach has also allowed performing univariate and multivariate
analyses. Second, the present meta-analysis reported quantitative evidence about the status of
one-carbon metabolism markers in the setting of N2O-related toxicity and highlighted the risk
of hyperhomocysteinemia and high methylmalonic acidemia. Third, the meta-analysis of case
reports allowed the compilation of unselected patients, thereby reducing the risk of population
heterogeneity. The analysis of bias did not reveal a significant stratification of the analyzed
population. We acknowledge several limitations. First, we used data extracted from available
case reports through a systematic retrospective search. This strategy carries the risk of missing data.
Second, laboratory findings were not available for all patients, which resulted in a decrease in the
statistical power for univariate and multivariate analyses. Third, in the surgical setting, thromboembolic
events potentially associated with N2O-induced hyperhomocysteinemia could have been mistakenly
attributed to the postoperative context, leading to a potential underestimation of the thromboembolic
risk associated with N2O exposure [36,41–47]. Fourth, in the present systematic review, the exclusion of
non-English case reports could have potentially led to selection bias. However, a study that examined
the influence of non-English publications on combined estimates of published meta-analyses did
not reveal a significant effect after the exclusion of non-English publications [48]. Fifth, because our
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meta-analysis focuses on single patient reports or small case series, we cannot evaluate the frequency of
events related to N2O-induced toxicity. These events may be relatively rare as N2O is widely used. Our
data point out the need to perform large population studies to better report on N2O-induced toxicity.
5. Conclusions
This meta-analysis points out the association of N2O exposure with severe neurological and
hematological manifestations and altered one-carbon metabolism markers. These findings lead to
raising awareness among the medical community urgently about the risk of N2O exposure and
particularly in the recreational setting among young people. Population studies are warranted
to evaluate whether the correction of vitamin B12 deficiency prevents N2O-related toxicity in the
context of anesthesia and recreational use, particularly in countries with a high prevalence of vitamin
B12 deficiency.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/4/551/s1,
Table S1: Detail of the Twenty-Nine Studies Excluded from the Systematic Review; Table S2: Detail of the Studies
Retained in the Systematic Review; Table S3: Variables Associated with Regular Nitrous Oxide Exposure in
Univariate Analyses; Table S4: Association Between the Amount of Nitrous Oxide (N2O) Exposure and Main
Clinical, Laboratory, and Magnetic Resonance Findings of the N2O-Related Disease; Figure S1: Assessment of study
bias induced by population stratification using principal component analysis; Figure S2: (a) Worldwide landscape of
serum or plasma vitamin B12 concentrations among patients with N2O-induced toxicity. (b) Worldwide prevalence
of subjects with low serum or plasma vitamin B12 concentrations among apparently healthy individuals.
Author Contributions: A.O.: literature review and data extraction; data synthesis and statistical analysis;
drafting/revision of the manuscript; analysis and interpretation of data; approved the final draft; M.J.: literature
review and data extraction; drafting/revision of the manuscript; approved the final draft; J.L.: literature review
and data extraction; drafting/revision of the manuscript; approved the final draft; O.H.: literature review and
data extraction; approved the final draft; C.F.: literature review and data extraction; approved the final draft;
C.S.: literature review and data extraction; approved the final draft; E.L.: literature review and data extraction;
approved the final draft; M.W.: literature review and data extraction; approved the final draft; P.F.T.: literature
review and data extraction; approved the final draft; R.G.: drafting/revision of the manuscript; analysis and
interpretation of data; approved the final draft; J.-L.G.: study concept; literature review; drafting/revision of the
manuscript; analysis and interpretation of data; approved the final draft.
Funding: This research was funded by institutional funding from i-Site Lorraine University of Excellence
(ANR-15-IDEX-04-LUE) and by FHU ARRIMAGE and INSERM UMR_S_1256.
Acknowledgments: We thank the administrative and technical staff of INSERM UMR_S_1256.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Erving, H.W. The discoverer of anaesthesia: Dr. Horace wells of hartford. Yale J. Biol. Med. 1933, 5, 421–430.
[PubMed]
2. Finder, S.G. Lessons from history: Horace wells and the moral features of clinical contexts. Anesth. Prog.
1995, 42, 1–6.
3. Randhawa, G.; Bodenham, A. The increasing recreational use of nitrous oxide: History revisited. Br. J. Anaesth.
2016, 116, 321–324. [CrossRef] [PubMed]
4. Garakani, A.; Jaffe, R.J.; Savla, D.; Welch, A.K.; Protin, C.A.; Bryson, E.O.; McDowell, D.M. Neurologic,
psychiatric, and other medical manifestations of nitrous oxide abuse: A systematic review of the case
literature. Am. J. Addict. 2016, 25, 358–369. [CrossRef] [PubMed]
5. Lassen, H.C.; Henriksen, E.; Neukirch, F.; Kristensen, H.S. Treatment of tetanus; severe bone-marrow
depression after prolonged nitrous-oxide anaesthesia. Lancet (Lond. Engl.) 1956, 270, 527–530. [CrossRef]
6. Amess, J.A.; Burman, J.F.; Rees, G.M.; Nancekievill, D.G.; Mollin, D.L. Megaloblastic haemopoiesis in patients
receiving nitrous oxide. Lancet (Lond. Engl.) 1978, 2, 339–342. [CrossRef]
7. Reuters, T. Endnote x7; Thomson Reuters: Philadelphia, PA, USA, 2013.
8. Stroup, D.F.; Berlin, J.A.; Morton, S.C.; Olkin, I.; Williamson, G.D.; Rennie, D.; Moher, D.; Becker, B.J.; Sipe, T.A.;
Thacker, S.B. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis
of observational studies in epidemiology (moose) group. JAMA 2000, 283, 2008–2012. [CrossRef]
J. Clin. Med. 2019, 8, 551 16 of 18
9. Fedosov, S.N.; Brito, A.; Miller, J.W.; Green, R.; Allen, L.H. Combined indicator of vitamin b12 status:
Modification for missing biomarkers and folate status and recommendations for revised cut-points. Clin. Chem.
Lab. Med. 2015, 53, 1215–1225. [CrossRef]
10. DeLong, E.R.; DeLong, D.M.; Clarke-Pearson, D.L. Comparing the areas under two or more correlated
receiver operating characteristic curves: A nonparametric approach. Biometrics 1988, 44, 837–845. [CrossRef]
11. Efron, B.; Tibshirani, R.J. An inTroduction to the Bootstrap; Taylor & Francis: Abingdon, UK, 1994.
12. Organization of Word Health. Iron Deficiency Anaemia Assessment, Prevention, and Control a Guide for
Programme Managers. Available online: http://www.who.int/nutrition/publications/en/ida_assessment_
prevention_control.pdf (accessed on 27 September 2018).
13. Bosco, P.; Gueant-Rodriguez, R.M.; Anello, G.; Barone, C.; Namour, F.; Caraci, F.; Romano, A.; Romano, C.;
Gueant, J.L. Methionine synthase (mtr) 2756 (a –>g) polymorphism, double heterozygosity methionine
synthase 2756 ag/methionine synthase reductase (mtrr) 66 ag, and elevated homocysteinemia are three risk
factors for having a child with down syndrome. Am. J. Med. Genet. Part A 2003, 121, 219–224. [CrossRef]
14. Brunaud, L.; Alberto, J.M.; Ayav, A.; Gerard, P.; Namour, F.; Antunes, L.; Braun, M.; Bronowicki, J.P.;
Bresler, L.; Gueant, J.L. Vitamin b12 is a strong determinant of low methionine synthase activity and DNA
hypomethylation in gastrectomized rats. Digestion 2003, 68, 133–140. [CrossRef] [PubMed]
15. Ortiou, S.; Alberto, J.M.; Gueant, J.L.; Merten, M. Homocysteine increases methionine synthase mrna level in
caco-2 cells. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 2004, 14, 407–414.
16. Bosco, P.; Gueant-Rodriguez, R.M.; Anello, G.; Spada, R.; Romano, A.; Fajardo, A.; Caraci, F.; Ferri, R.;
Gueant, J.L. Association of homocysteine (but not of mthfr 677 c > t, mtr 2756 a > g, mtrr 66 a > g and tcn2
776 c>g) with ischaemic cerebrovascular disease in sicily. Thromb. Haemost. 2006, 96, 154–159.
17. Alberto, J.M.; Hamelet, J.; Noll, C.; Blaise, S.; Bronowicki, J.P.; Gueant, J.L.; Delabar, J.M.; Janel, N.
Mice deficient in cystathionine beta synthase display altered homocysteine remethylation pathway.
Mol. Genet. Metab. 2007, 91, 396–398. [PubMed]
18. Candito, M.; Rivet, R.; Herbeth, B.; Boisson, C.; Rudigoz, R.C.; Luton, D.; Journel, H.; Oury, J.F.; Roux, F.;
Saura, R.; et al. Nutritional and genetic determinants of vitamin b and homocysteine metabolisms in neural
tube defects: A multicenter case-control study. Am. J. Med. Genet. Part A 2008, 146, 1128–1133.
19. Fofou-Caillierez, M.B.; Mrabet, N.T.; Chery, C.; Dreumont, N.; Flayac, J.; Pupavac, M.; Paoli, J.; Alberto, J.M.;
Coelho, D.; Camadro, J.M.; et al. Interaction between methionine synthase isoforms and mmachc:
Characterization in cblg-variant, cblg and cblc inherited causes of megaloblastic anaemia. Hum. Mol. Genet.
2013, 22, 4591–4601. [CrossRef] [PubMed]
20. Ghemrawi, R.; Pooya, S.; Lorentz, S.; Gauchotte, G.; Arnold, C.; Gueant, J.L.; Battaglia-Hsu, S.F. Decreased vitamin
b12 availability induces er stress through impaired sirt1-deacetylation of hsf1. Cell Death Dis. 2013, 4, e553. [CrossRef]
[PubMed]
21. Bassila, C.; Ghemrawi, R.; Flayac, J.; Froese, D.S.; Baumgartner, M.R.; Gueant, J.L.; Coelho, D.
Methionine synthase and methionine synthase reductase interact with mmachc and with mmadhc. Biochim. Et
Biophys. Acta 2017, 1863, 103–112. [CrossRef]
22. Green, R.; Allen, L.H.; Bjorke-Monsen, A.L.; Brito, A.; Gueant, J.L.; Miller, J.W.; Molloy, A.M.; Nexo, E.;
Stabler, S.; Toh, B.H.; et al. Vitamin b12 deficiency. Nat. Rev. Dis. Primers 2017, 3, 17040. [CrossRef]
23. Green, R. Vitamin b12 deficiency from the perspective of a practicing hematologist. Blood 2017, 129, 2603–2611.
[CrossRef]
24. Hathout, L.; El-Saden, S. Nitrous oxide-induced b(1)(2) deficiency myelopathy: Perspectives on the clinical
biochemistry of vitamin b(1)(2). J. Neurol. Sci. 2011, 301, 1–8. [CrossRef]
25. Dinn, J.J.; McCann, S.; Wilson, P.; Reed, B.; Weir, D.; Scott, J. Animal model for subacute combined
degeneration. Lancet (Lond. Engl.) 1978, 2, 1154. [CrossRef]
26. van der Westhuyzen, J.; Fernandes-Costa, F.; Metz, J. Cobalamin inactivation by nitrous oxide produces
severe neurological impairment in fruit bats: Protection by methionine and aggravation by folates. Life Sci.
1982, 31, 2001–2010. [CrossRef]
27. Metz, J. Cobalamin deficiency and the pathogenesis of nervous system disease. Annu. Rev. Nutr. 1992, 12, 59–79.
[CrossRef]
28. Cantrill, R.C.; Oldfield, M.; van der Westhuyzen, J.; McLoughlin, J. Protein profile of the myelin membrane
of the fruit bat rousettus aegyptiacus. Comp. Biochem. Physiol. B 1983, 76, 881–884. [CrossRef]
J. Clin. Med. 2019, 8, 551 17 of 18
29. Deacon, R.; Purkiss, P.; Green, R.; Lumb, M.; Perry, J.; Chanarin, I. Vitamin b12 neuropathy is not due to
failure to methylate myelin basic protein. J. Neurol. Sci. 1986, 72, 113–117. [CrossRef]
30. Veber, D.; Mutti, E.; Galmozzi, E.; Cedrola, S.; Galbiati, S.; Morabito, A.; Tredici, G.; La Porta, C.A.;
Scalabrino, G. Increased levels of the cd40:Cd40 ligand dyad in the cerebrospinal fluid of rats with vitamin
b12(cobalamin)-deficient central neuropathy. J. Neuroimmunol. 2006, 176, 24–33. [CrossRef] [PubMed]
31. Scalabrino, G.; Nicolini, G.; Buccellato, F.R.; Peracchi, M.; Tredici, G.; Manfridi, A.; Pravettoni, G. Epidermal
growth factor as a local mediator of the neurotrophic action of vitamin b(12) (cobalamin) in the rat central
nervous system. FASEB J. 1999, 13, 2083–2090. [CrossRef]
32. Scalabrino, G.; Tredici, G.; Buccellato, F.R.; Manfridi, A. Further evidence for the involvement of epidermal
growth factor in the signaling pathway of vitamin b12 (cobalamin) in the rat central nervous system.
J. Neuropathol. Exp. Neurol. 2000, 59, 808–814. [PubMed]
33. Scalabrino, G.; Mutti, E.; Veber, D.; Aloe, L.; Corsi, M.M.; Galbiati, S.; Tredici, G. Increased spinal cord ngf
levels in rats with cobalamin (vitamin b12) deficiency. Neurosci. Lett. 2006, 396, 153–158. [CrossRef]
34. Scalabrino, G.; Carpo, M.; Bamonti, F.; Pizzinelli, S.; D’Avino, C.; Bresolin, N.; Meucci, G.; Martinelli, V.;
Comi, G.C.; Peracchi, M. High tumor necrosis factor-alpha [corrected] levels in cerebrospinal fluid of
cobalamin-deficient patients. Ann. Neurol. 2004, 56, 886–890. [CrossRef] [PubMed]
35. Kondo, H.; Osborne, M.L.; Kolhouse, J.F.; Binder, M.J.; Podell, E.R.; Utley, C.S.; Abrams, R.S.; Allen, R.H.
Nitrous oxide has multiple deleterious effects on cobalamin metabolism and causes decreases in activities of
both mammalian cobalamin-dependent enzymes in rats. J. Clin. Investig. 1981, 67, 1270–1283. [CrossRef]
[PubMed]
36. Myles, P.S.; Chan, M.T.; Leslie, K.; Peyton, P.; Paech, M.; Forbes, A. Effect of nitrous oxide on plasma
homocysteine and folate in patients undergoing major surgery. Br. J. Anaesth. 2008, 100, 780–786. [CrossRef]
37. Home Office. Drug Misuse: Findings from the 2016/17 Crime Survey for England and Wales.
Available online: https://assets.Publishing.Service.Gov.Uk/government/uploads/system/uploads/attachment_
data/file/642738/drug-misuse-2017-hosb1117.Pdf (accessed on 28 July 2018).
38. Kaar, S.J.; Ferris, J.; Waldron, J.; Devaney, M.; Ramsey, J.; Winstock, A.R. Up: The rise of nitrous oxide abuse.
An international survey of contemporary nitrous oxide use. J. Psychopharmacol. 2016, 30, 395–401. [CrossRef]
39. Survey, G.D. Key Findings from the Global Drug Survey 2016 (data collected nov 15 January 16).
Available online: https://www.Globaldrugsurvey.Com/past-findings/the-global-drug-survey-2016-findings/
(accessed on 28 July 2018).
40. Imberger, G.; Orr, A.; Thorlund, K.; Wetterslev, J.; Myles, P.; Moller, A.M. Does anaesthesia with nitrous oxide
affect mortality or cardiovascular morbidity? A systematic review with meta-analysis and trial sequential
analysis. Br. J. Anaesth. 2014, 112, 410–426. [CrossRef]
41. Amouzou, E.K.; Chabi, N.W.; Adjalla, C.E.; Rodriguez-Gueant, R.M.; Feillet, F.; Villaume, C.; Sanni, A.; Gueant, J.L.
High prevalence of hyperhomocysteinemia related to folate deficiency and the 677c–>t mutation of the gene encoding
methylenetetrahydrofolate reductase in coastal west africa. Am. J. Clin. Nutr. 2004, 79, 619–624. [CrossRef] [PubMed]
42. Bosco, P.; Anello, G.; Ferri, R.; Gueant-Rodriguez, R.M.; Gueant, J.L. Heterogeneity of association between mthfr
and stroke among european regions: Additional population studies are needed in italy. Stroke 2006, 37, 761–762.
[CrossRef] [PubMed]
43. Gueant-Rodriguez, R.M.; Juilliere, Y.; Nippert, M.; Abdelmouttaleb, I.; Herbeth, B.; Aliot, E.; Danchin, N.;
Gueant, J.L. Left ventricular systolic dysfunction is an independent predictor of homocysteine in
angiographically documented patients with or without coronary artery lesions. J. Thromb. Haemost. Jth
2007, 5, 1209–1216. [CrossRef]
44. Peyrin-Biroulet, L.; Rodriguez-Gueant, R.M.; Chamaillard, M.; Desreumaux, P.; Xia, B.; Bronowicki, J.P.;
Bigard, M.A.; Gueant, J.L. Vascular and cellular stress in inflammatory bowel disease: Revisiting the role of
homocysteine. Am. J. Gastroenterol. 2007, 102, 1108–1115. [CrossRef]
45. Spada, R.S.; Stella, G.; Calabrese, S.; Bosco, P.; Anello, G.; Gueant-Rodriguez, R.M.; Romano, A.; Benamghar, L.;
Fontaine, T.; Gueant, J.L. Association of vitamin b12, folate and homocysteine with functional and pathological
characteristics of the elderly in a mountainous village in sicily. Clin. Chem. Lab. Med. 2007, 45, 136–142.
[CrossRef]
46. Gueant-Rodriguez, R.M.; Spada, R.; Moreno-Garcia, M.; Anello, G.; Bosco, P.; Lagrost, L.; Romano, A.;
Elia, M.; Gueant, J.L. Homocysteine is a determinant of apoa-i and both are associated with ankle brachial
index, in an ambulatory elderly population. Atherosclerosis 2011, 214, 480–485. [CrossRef] [PubMed]
J. Clin. Med. 2019, 8, 551 18 of 18
47. den Heijer, M.; Koster, T.; Blom, H.J.; Bos, G.M.; Briet, E.; Reitsma, P.H.; Vandenbroucke, J.P.; Rosendaal, F.R.
Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N. Engl. J. Med. 1996, 334, 759–762.
[CrossRef] [PubMed]
48. Juni, P.; Holenstein, F.; Sterne, J.; Bartlett, C.; Egger, M. Direction and impact of language bias in meta-analyses
of controlled trials: Empirical study. Int. J. Epidemiol. 2002, 31, 115–123. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
